Intellia Therapeutics, Inc. (NTLA)
10.55
-0.86
(-7.54%)
USD |
NASDAQ |
Nov 12, 16:00
10.79
+0.24
(+2.27%)
After-Hours: 06:39
Intellia Therapeutics Enterprise Value : 1.236B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.236B |
| November 11, 2026 | 1.356B |
| November 10, 2026 | 1.323B |
| November 09, 2026 | 1.455B |
| November 06, 2026 | 1.348B |
| November 05, 2026 | 1.313B |
| November 04, 2026 | 1.483B |
| November 03, 2026 | 1.419B |
| November 02, 2026 | 1.391B |
| October 30, 2026 | 1.505B |
| October 29, 2026 | 1.612B |
| October 28, 2026 | 1.624B |
| October 27, 2026 | 1.478B |
| October 26, 2026 | 1.335B |
| October 23, 2026 | 1.328B |
| October 22, 2026 | 1.321B |
| October 21, 2026 | 1.390B |
| October 20, 2026 | 1.417B |
| October 19, 2026 | 1.380B |
| October 16, 2026 | 1.358B |
| October 15, 2026 | 1.347B |
| October 14, 2026 | 1.359B |
| October 13, 2026 | 1.426B |
| October 12, 2026 | 1.520B |
| October 09, 2026 | 1.589B |
| Date | Value |
|---|---|
| October 08, 2026 | 1.523B |
| October 07, 2026 | 1.398B |
| October 06, 2026 | 1.491B |
| October 05, 2026 | 1.544B |
| October 02, 2026 | 1.476B |
| October 01, 2026 | 1.456B |
| September 30, 2026 | 1.447B |
| September 29, 2026 | 1.320B |
| September 28, 2026 | 1.235B |
| September 25, 2026 | 1.281B |
| September 24, 2026 | 1.338B |
| September 23, 2026 | 1.362B |
| September 22, 2026 | 1.412B |
| September 21, 2026 | 1.347B |
| September 18, 2026 | 1.335B |
| September 17, 2026 | 1.352B |
| September 16, 2026 | 1.244B |
| September 15, 2026 | 1.226B |
| September 14, 2026 | 1.298B |
| September 11, 2026 | 1.279B |
| September 10, 2026 | 1.306B |
| September 09, 2026 | 1.345B |
| September 08, 2026 | 1.419B |
| September 04, 2026 | 1.419B |
| September 03, 2026 | 1.411B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 7.085B |
| Beam Therapeutics, Inc. | 1.686B |
| Prime Medicine, Inc. | 720.48M |
| 10X Genomics, Inc. | 7.271B |
| Moderna, Inc. | 92.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -127.48M |
| Revenue (Quarterly) | 7.163M |
| Total Expenses (Quarterly) | 134.65M |
| EPS Diluted (Quarterly) | -0.9094 |
| Gross Profit Margin (Quarterly) | 73.15% |
| Profit Margin (Quarterly) | -1.78K% |
| Earnings Yield | -31.72% |
| Normalized Earnings Yield | -30.99 |